Litigation Innovation: Article One Partners Seeks Art To Invalidate Patents
Executive Summary
Brand-name drug manufacturers have a new nemesis in their patent wars: Article One Partners. The group is gathering data to challenge the validity of high-profile patents in litigation
You may also be interested in...
Merck Wins Singulair Patent Battle With Teva
A federal court rules that broad scientific presentations do not constitute prior art in this case, a finding that gives Merck three years to consider an OTC switch.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.